The preclinical pharmacology of 'Arimidex' (Anastrozole; ZD1033) - A potent, selective aromatase inhibitor

Journal of Steroid Biochemistry and Molecular Biology

Volumn 58, Issue 4, 1996, Pages 439-445

  Dukes, Michael ^a   Edwards, Philip N ^a   Large, Michael ^a   Smith, Ian K ^a   Boyle, Thomas ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; DEOXYCORTICOSTERONE; DEXAMETHASONE; ESTRADIOL; FADROZOLE; FORMESTANE; HYDROCORTISONE; METYRAPONE; STEROID 11BETA MONOOXYGENASE; TESTOSTERONE;

ADRENAL FUNCTION; ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATTLE; CONTROLLED STUDY; DOG; FEMALE; GUINEA PIG; HORMONE SYNTHESIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MICROSOME; MONKEY; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OVULATION; PLACENTA; POTASSIUM BLOOD LEVEL; RAT; SEMINAL VESICLE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALIA; BOS TAURUS; CANIS FAMILIARIS; CAVIA PORCELLUS; SUS SCROFA;

EID: 0030200208     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(96)00064-7     Document Type: Article

References (23)

1. 1. Howell A., DeFreind D. and Anderson A.: Mechanisms of response and resistance to endocrine therapy for breast cancer and the development of new treatments. Rev. Endocr.-Rel. Cancer 43 (1993) 5-21.
2. 2. Wakeling A. E., Dukes M. and Bowler J.: A potent specific pure antioestrogen with clinical potential. Cancer Res. 51 (1991) 3867-3873.
3. 3. Brodie A. M. H., Schwarzel W. C., Shaikh A. A. and Brodie H. J.: The effect of an aromatase inhibitor, 4-hydroxy-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100 (1977) 1684-1695.
4. 4. Gower D. B.: Modifiers of steroid-hormone metabolism. A review of their chemistry, biochemistry and clinical applications. J. Steroid Biochem. 5 (1974) 501-523.
5. 5. Franz C. and Longcope C.: Androgen and estrogen metabolism in male rhesus monkeys. Endocrinology 105 (1979) 869-874.
6. 6. Ryan K. J.: Biological aromatization of steroids. J. Biol. Chem. 234 (1959) 268-272.
7. 7. Thompson E. A. and Siiteri P. K.: The involvement of human placental microsomal cytochrome P-450 in aromatization. J. Biol. Chem. 249 (1974) 5373-5378.
8. 8. Ellinwood W. E., Hess D. L., Roselli C. E., Spies H. G. and Resko J. A.: Inhibition of aromatization stimulates LH and testosterone secretion in adult male rhesus monkeys. J. Clin. Endocr. Metab. 59 (1984) 1088-1096.
9. 9. Santen R. J., Demers L. M., Adlercreutz H., Harvey H., Santner S., Sanders S. and Lipton A.: Inhibition of aromatase with CGS 16949A in postmenopausal women. J. Clin. Endocr. Metab. 68 (1989) 99-106.
10. 10. Beretta K. R., Hoeffken K., Kvinnsland S., Trunet P., Chaudri A. S., Bhatnagar A. S., Goldhirsch A. and Cavalli F.: CGS 16949A, a new aromatase inhibitor in die treatment of breast cancer - a phase I study. Ann. Oncol. 1 (1990) 421-426.
11. 11. Lipton A., Harvey H. A., Demers L. M., Hanagan J. R., Mulagha M. T., Kochak G. M., Fitzsimmons S., Sanders S. I. and Santen R. J.: A phase I trial of CGS 16949A, a new aromatase inhibitor. Cancer 65 (1990) 1279-1285.
12. 12. Chambon Y., Picard F. and Jaquen J. P.: Variations in adrenal gland weights of rats under the effect of castration and administration of sex hormones. Compt. Rend. Sce. Soc. Biol. Filial. 163 (1969) 1688-1692.
13. 13. Kitay J. I. Effects of estrogen and androgen on the adrenal cortex of the rat. In Functions of the Adrenal Cortex. Vol. 2 (Edited by W. McKerns). Appleton Century Crofts, New York (1968) pp. 775-811
14. 14. Lamberts S. W. J., Bruining H. A., Marzouk H., Zuiderwijk J., Uitterlinden P., Bliijd J. J., Hackeng W. H. L. and de Jong F. H.: The new aromatase inhibitor CGS 16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro. J. Clin. Endocr. Metab. 69 (1989) 896-901.
15. 15. Aabo K. and De Coster R.: Hypertension during high-dose ketoconazole treatment: a probable mineralocorticosteroid effect. Lancet 12 (1987) 637-638.
16. 16. Adlin E. V. and Channick B. J.: Effects of prolonged inhibition of 11β-hydroxylase in the dog. Endocrinology 78 (1966) 511-521.
17. 17. Hausler A., Monnet G., Borer C. and Bhatnagar A. S.: Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal. J. Steroid Biochem. 34 (1989) 567-570.
18. 18. Dowsett M., Stein R. C., Mehta A. and Coombes R. C.: Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin. Endocr. 32 (1990) 623-634.
19. 19. Birmingham M. K., De Nicola A. F., Oliver J. T., Traikov H., Birmingham M. L., Holzbauer M., Godden U. and Sharman D. F.: Production of steroids in vivo by regenerated adrenal glands of hypertensive and normotensive rats. Endocrinology 93 (1973) 297-310.
20. 20. Wakeling A. E. and Bowler J.: Biology and mode of action of pure antioestrogens. J. Steroid Biochem. 30 (1988) 141-147.
21. 21. Plourde P. V., Yates R. A., Dyroff M., Dukes M., Dowsett M. A., Demers L. M., Webster A. The effect of Arimidex, a new potent aromatase inhibitor, on circulating estrogens in post-menopausal women. Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology, 12 (1993) 91 Abstr. 165
22. 22. Plourde P. V., Dyroff M. and Dukes M.: Arimidex: a potent and selective fourth generation aromatase inhibitor. Breast Cancer Res. Treat. 30 (1994) 103-111.
23. 23. Geisler J., Lonning P. E., Dowsett M., King N., Lundgren S., Ottestad L., Kormeset P. O. and Walton P. L.: A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer. The Breast 4 (1995) 227.